PCSK9 Inhibitors and Neurocognitive Adverse Drug Reactions: Analysis of Individual Case Safety Reports from the Eudravigilance Database.

Gabriella di MauroAlessia ZinziCristina ScavoneAnnamaria MascoloMario GaioLiberata SportielloCarmen FerrajoloConcetta RafanielloFrancesco RossiAnnalisa Capuano

Published in: Drug safety (2020)

Our results demonstrated that 22.7% of all ICSRs reporting alirocumab or evolocumab as suspect drugs described the occurrence of neuropsychiatric ADRs. The ROR showed that evolocumab and alirocumab had a higher reporting probability of neurological ADRs compared with statins. Further data from real-life contexts are needed.

Keyphrases

adverse drug
low density lipoprotein
electronic health record
drug induced
emergency department
cardiovascular disease
risk assessment
bipolar disorder
big data
data analysis